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Effet de la dronédarone sur la fonction rénale de volontaires sains masculins 
But 
Evaluer l'effet de la dronédarone sur la fonction rénale et le transport tubulaire des cations. 
Méthodes 
Douze sujets masculins en bonne santé ont été inclus dans une étude randomisée, croisée, 
comparée à un placebo, en double aveugle. Ils ont reçu 400 mg de dronédarone ou un placebo 
deux fois par jour pendant sept jours. Des tests fonctionnels rénaux ont été effectués avant le 
traitement et en cours de traitement après une standardisation stricte des appmis, par détermi-
nation de la clairance de la créatinine, de la sinistrine, du para-amino-hippurate (P AH) et du 
N-méthylnicotinamide (NMN) et de l'excrétion des électrolytes. 
Résultats 
Comparée au placebo, la dronédarone a réduit de manière significative la clairance de la 
créatinine (en moyenne 138-119 ml/min après dronédarone vs 142-149 ml/min après placebo) 
et la clairance du NMN (448-368 ml/min vs 435-430 ml/min), mais n'a pas eu d'effet sur la 
clairance rénale de la sinistrine, du PAH ou sur d'autres paramètres rénaux. 
Conclusion 
La dronédarone réduit la clairance rénale de la créatinine et du NMN d'environ 18%, sans 
évidence d'effet sur la filtration glomérulaire, sur le flux plasmatique rénal ou sur les 
échanges électrolytiques. Cela suggère une inhibition spécifique partielle du transport 
tubulaire organique des cations (OCT). Une augmentation limitée de la créatininémie est donc 
à attendre sous traitement de dronédarone, sans que cela ne soit assimilable à une baisse de la 
fonction rénale. 
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What is already known about this subject What this study adds 
• Creatinine clearance (CL) is used to assess glomerular 
filtration rate (GFR). However, it is known to slightly 
overestimate the true GFR, due to renal tubular secretion 
of creatinine. 
• Dronedarone affects the renal handling of creatinine and 
N-methylnicotinamide, two cations, while leaving unchanged 
GFR, assessed through sinistrin CL, and renal plasma flow 
and anion secretion, assessed through para-amino-hippurate 
CL • During phase 1-111 clinical trials, a 10-150/o increase in 
serum creatinine has been observed both in healthy 
subjects and patients receiving the new antiarrhythmic 
agent dronedarone. 
• This suggests a specific action of dronedarone on renal 
organic cation transport explaining the limited, reversible 
effect of dronedarone on serum creatinine, which must not 
be interpreted as reflecting an impairment of renal function, 
but which may indicate an interaction potential with cationic 
drugs. 
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Ai ms 
To assess the effects of dronedarone on renal function and tubular cation handling. 
Methods 
Twelve healthy males were enrolled in a randomized, cross-over, placebo-controlled, 
double-blind study. They received 400 mg dronedarone or placebo twice daily for 
7 days. Baseline and on-treatment renal function tests were performed under strict 
standardization of intakes, by assessing creatinine, sinistrin, para-amino-hippurate 
(PAH) and N-methylnicotinamide (NMN) CLs, and electrolyte excretion. 
Results 
Compared with placebo, dronedarone significantly decreased renal creatmme CL 
(mean 138-119 ml min-1 after dronedarone vs. 142-149 ml min-1 after placebo) and 
NMN CL (448-368 ml min-1 vs. 435-430 ml min-1), but did not alter renal sinistrin 
CL, PAH CL and other renal parameters. 
Conclusions 
Dronedarone reduces renal creatinine and NMN clearance by about 180/o, without 
evidence of an effect on GFR, renal plasma flow or electrolyte exchanges. This 
suggests a specific partial inhibition of tubular organic cation transporters (OCT). A 
limited increase in serum creatinine is therefore expected with dronedarone treatment, 
but does not mean there is a decline in renal function. 
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Introduction 
Creatinine, an endogenous cation produced mainly by 
muscle metabolism, is the most widely used marker to 
assess glomerular filtration rate (GFR) in the clinical 
setting. However, creatinine clearance is known to 
slightly overestimate the true GFR, as it is secreted up to 
20% across the renal tubule through an active cationic 
transport, in addition to the amount filtered at the glom-
erulus [1]. Several drugs, such as cimetidine and trime-
thoprim [2, 3], are known to interfere with creatinine 
transport across tubular epithelial cells. Such drugs 
inhibit the organic cation transport system located in the 
renal proximal tubule, thus decreasing creatinine clear-
ance (CLcr) and increasing serum creatinine concentra-
tion without altering the GFR itself. This effect of 
cimetidine has been used in clinical practice to improve 
the accuracy of CLc, measurement as an estimation of 
GFR [4]. 
Dronedarone is a noniodinated benzoforan derivative 
with pharrnacological activity sirnilar to arniodarone 
[5-7], to which it is structurally related, and shares elec-
trophysiological characteristics of all four Vaughan-
Williarns classes of antiarrhythrnics [8-10]. It is less 
likely to induce the thyroid adverse events observed with 
amiodarone. Targeted indications are atrial fibrillation 
and fiutter. During phase I-III clinical trials, a 10-15% 
increase in serum creatinine has been regularly observed 
both in healthy subjects and patients receiving dronedar-
one, without any clinical or laboratory evidence of renal 
structural damage. This effect seemed to be rapid and 
reversible, with a quick retum to baseline values occur-
ring after study drug discontinuation. In animal studies, 
no histological changes were noted in the kidneys 
despite a slight increase in serum creatinine concentra-
tions (5-15%) [11]. An artefactual interference with 
creatinine measurement methods (e.g. Jaffé method) 
was excluded. 
Carrier-mediated transporters play an important role 
in renal tubular reabsorption and secretion of a number 
of endogenous and exogenous compounds [12]. A 
majority of transporters represent oligospecific carrier 
proteins involved .in the transf er of specific metabolic 
and nutritional compounds (SLC19 transpmter farnily). 
By contrast, drugs and toxins are transferred by a limited 
number of polyspecific transporters accepting com-
pounds of variable size and molecular structure. In 
addition to the ATP-binding-cassette farnily (including 
P-glycoprotein and related proteins), three familles of 
ATP-independent polyspecific transporters have been 
identified to date: the H+-oligopeptide cotransporter 
farnily SLC15 (solute carrier farnily 15), the solute 
carrier organic anion transporter farnily SLCO (SLC21) 
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and the organic cation-anion-zwitterion transporter 
farnily SLC22. The latter includes three organic cation 
transporters (OCTl-3), four organic anion transporters 
(OATl-4), one urate transporter, three transporters of 
camitine and/or cations (OCTNl,2 and CT2) and six 
gene products of unidentified fonction [13]. The distri-
bution of these various carrier subtypes throughout the 
body is not completely elucidated. However, most sub-
types are expressed in the kidney, consistent with its 
elirnination fonction, with the main subtype being prob-
ably OCT2 [14-16]. The transporters involved in renal 
tubular secretion contribute to the elimination of organic 
compounds that are weakly filtrated, owing to strong 
protein binding. Transporters are also found in other 
organs involved in the defence against toxins, such as the 
liver, the intestine and the placenta [17], and this mecha-
nism is saturable [18]. 
Creatinine, a zwitterion, is secreted to a moderate 
extent by the renal tubular cation transport system and 
minimally by anion transporters [19]. It has low affinity 
for OCT2, with a Michaelis constant of 4000 µmol l-1, 
and its renal transport is readily inhibited by various 
drugs [12]. As a cation, dronedarone, though mainly 
elirninated through biliary excretion, may compete for 
the cation transport pathway and thus inhibit creatinine 
secretion in a cimetidine-like way, thereby leading to a 
limited increase in serum creatinine concentrations. 
Considering the use of creatinine clearance or serum 
creatinine concentration to assess renal fonction, it 
appeared suitable to confirm the hypothesis of an inter-
ference of dronedarone with such tests, while excluding 
a direct action of this new drug on GFR or renal 
integrity. 
To investigate GFR independently of cation transport, 
sinistrin, an inulin-like polyfructosan with high solubil-
ity, represents an ideal marker as it is almost exclusively 
elirninated by filtration [1, 20]. N-methylnicotinarnide 
(NMN), produced during tryptophan and niacin metabo-
lism, is an endogenous substrate of the active cation 
secretion system, and the assessment of its clearance has 
been proposed to test the organic cation secretion and 
the renal plasma flow [21-23]. On the other band, para-
amino-hippurate (PAH) is used to study the active 
anionic secretion; as it is highly extracted, PAH has also 
been established as the standard marker for deterrnina-
tion of the renal plasma fiow [l]. 
The aim of this phase I study was thus to evaluate the 
effects of dronedarone, compared with placebo, on 
creatinine clearance and on glomerular filtration rate 
assessed by renal sinistrin clearance, in healthy subjects. 
Secondary objectives were to evaluate the effects of 
dronedarone on two markers of tubular transport and 
renal blood flow, one exogenous substrate of the anionic 
transport system (PAR) and one endogenous substrate of 
the cationic transport system (NMN). 
Methods 
Subjects 
Twelve healthy male subjects with mean age of 26 years 
(range 19-38 years), mean weight of 68 kg (range 
56-88 kg), mean height of 179 cm (range 169-192 cm) 
and mean body mass index (BMI) of 21 kg m-2 (range 
19-24.6 kg m-2) gave their written informed consent 
before initiation of the study, after the protocol had been 
approved by the Research Ethics Committee of the Uni-
versity Hospital of Lausanne, Switzerland. All subjects 
were considered healthy after detailed medical history, 
physical examination (including a 12-lead electrocardio-
gram, echocardiography and a 24 h Holter recording) 
and extensive laboratory tests (haematology, biochemis-
try, serology and urinalysis). No medication was allowed 
within 2 weeks prior to dronedarone administration and 
throughout the duration of the study, except the use of 
acetaminophen in case of pain. 
Drugs 
Dronedarone 400 mg tablets were supplied by Sanofi-
Aventis (Montpellier, France). For determination of the 
sinistrin clearance, Inutest® vials of 5 g 20 m1-1 were 
purchased from Fresenius Kabi Austria GmbH (Graz, 
Austria). Sodium para-amino-hippurate (PAR) vials 
of 2 g 10 ml-1 were obtained from Clinalfa, Merck 
Biosciences AG (Laufelfingen, Switzerland). 
Study design and procedures 
This was a monocentre, randomized, placebo-
controlled, double-blind cross-over study. It consisted of 
two periods during which each subject received twice 
daily repeated doses of either 400 mg dronedarone or 
placebo for 7 days, separated by a 14 day washout 
period. The subjects underwent renal investigations on 
five occasions: on the day before treatment ( day -1) and 
on the last day of treatment ( day 7) of each period, then 
14 days after the last study drug administration. From 
the day before each renal investigation, subjects were on 
a diet with strict standardization of food and liquid 
intakes. A 24 h urine collection was obtained for mea-
surement of creatinine, osmolality, sodium and potas-
sium excretion on day -1. For the investigation, an 
intravenous catheter was inserted in each forearm 
(Optiva; Johnson & Johnson Medical, Arlington, TX), 
one for sinistrin and PAR infusion and one for blood 
sampling. Subjects received a standardized breakfast, 
followed by the study drug with 200 ml water. Sinistrin 
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and PAR infusion started 0.5 h after treatment adminis-
tration (or corresponding time on the days without treat-
ment). A loading dose of 18.75 mg kg-1œw sinistrin 
and 3.6 mg kg-1œw PAH was administered over 3 min 
to achieve quickly a pseudo-steady-state plasma concen-
tration of 75 mg 1-1 for sinistrin and 12 mg 1-1 for 
PAR. Immediately thereafter, a maintenance infusion 
designed to bring 9 mg h-1 of sinistrin and 7.2 mg h-1 of 
PAR per ml min-1 GFR (estimated from serum creati-
nine by the Cockroft-Gault formula) was started and 
maintained during 6 h, using a high-precision pump 
(Pilote C; Fresenius Vial, Brezins, France). Blood 
samples for measurement of plasma creatinine, sinistrin, 
PAR and NMN were collected before and at 2, 3.5, 5 and 
6.5 h after drug administration. The samples were cen-
trifuged and plasma was separated and stored at -20°C 
until analysis. The haematocrit of each sample was also 
assessed. Urine was collected from 2 to 3.5, 3.5-5 and 
5-6.5 h for creatinine, sinistrin, PAR and NMN mea-
surements, the volume determined and an aliquot stored 
at -20°C. A fixed amount of water (6 x 200 ml) was 
given for hydration during the investigation day. Before 
and after the treatment period, haematology and bio-
chemistry tests were repeated for safety assessment. 
No medication, xanthine containing drinks ( coffee, 
tea, coke) or alcohol were allowed during the investiga-
tion and treatment periods. Smoking and strenuous sport 
were prohibited during the entire study period. 
Ana/ytical methods 
Plasma and urine concentrations of sinistrin, PAH and 
NMN were determined by validated high-performance 
liquid chromatography (HPLC) methods with electro-
chemical detection (limit of detection 0.8 µg ml-1, pre-
cision between 6.3 and 9.7% in plasma and 4.2-10.2% 
in urine) and UV detection (limit of detection in plasma 
0.2 µg ml-1, precision between 3.3 and 4.4% in plasma, 
2.0-2.8% in urine) and after derivatization and using 
fluorescence detection (limit of detection 0.25 ng ml-1 in 
plasma, 8 ng ml-1 in urine, precision between 1.1 and 
3.3% in plasma and 5.6-8.3% in urine), respectively 
[24--26]. Creatinine was measured by the standard Jaffé 
colorimetric method. 
Data ana!ysis 
Creatinine, sinistrin, PAR and NMN renal clearances 
were calculated from the three urine collections 
(concentration = U, volume = V, duration = 11t) and 
from the geometric mean of the blood concentrations 
measured at each start and end of collection periods 
(concentration = P), using the following standard 
formula: 
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CLR = (U X V)/(P X 11t) [27] 
Knowing the infusion rate (R) of sinistrin and PAR, 
determined by careful assessment of the marker concen-
tration in the solution and of the flow rate of the pump 
[28], enabled the calculation of their respective systemic 
clearance: CLs = RJP. Systemic clearance calculated this 
way bas more inertia than renal clearance to reflect 
sudden and sh01i-term changes in kidney function [27]. 
For creatinine and NMN, systemic clearance was esti-
mated in a similar way, assuming a constant production 
rate (R) which was estimated for each subject as his 
average excretion rate throughout the study. 
Renal sinistrin clearance was considered the reference 
value for determination of the glomerular filtration rate. 
Renal blood flow was calculated from the renal and 
systemic PAR clearances and from the haematocrit: 
RBF = CLPAH/(1 - Ht). Renal creatinine clearance was 
also determined from the 24 h urine collection, which 
also allowed the measurement of excreted amounts of 
sodium, potassium and water. 
Statistico/ ana/ysis 
Statistical analysis was performed using a linear mixed 
eff ect model with fixed terms and a random tenn for 
subjects within sequence. The relative changes of clear-
ances from baseline to the 7th day of treatment were 
expressed in percent, based on means of log-transformed 
values and compared between dronedarone and placebo 
using ANOVA, which accounted for subject, sequence, 
period and time effects. 
Results 
Subjects 
Twenty subjects had to be screened to obtain 12 healthy 
male subjects for inclusion in the study protocol (five 
subjects were excluded because of benign arrhythmia in 
24 h Holter examination, and three declined for personal 
or convenience reasons). Ail enrolled subjects com-
pleted the study. 
Rena/ function tests 
Results are presented in Table 1 and Figure 1. No differ-
ences in the various clearances could be noted between 
the treatment periods at baseline. After 7 days of treat-
ment, dronedarone significantly affected renal creatinine 
clearance, which decreased by 17.7% (95% CI -31.7, 
-0.9) compared with placebo. Sinistrin clearance 
remained unaffected by dronedarone compared with 
placebo, with a variation of 3.4% (95% CI-20.4, 17.2). 
Renal clearance of NMN decreased by 17.0% (95% CI 
-31.58, 0.65) compared with placebo. Conversely, renal 
PAR clearance was not affected by dronedarone, with 
a variation of 5.8% (95% CI -22.5, 14.5). The compar-
ison of systemic clearance values indicated essentially 
similar changes (not shown). The ratio between renal 
creatinine and renal sinistrin clearances decreased after 
7 days of dronedarone treatment to an average of 1.2, 
while it remained unchanged at 1.4 after placebo. Simi-
larly, the ratio of renal NMN over renal PAH clearances 
decreased from 0.9 to 0.8 after dronedarone. 
No changes in urine fiow rate, osmolality, sodium and 
potassium excretions were observed between baseline 
and day 7 of dronedarone treatment compared with 
placebo. 
Safety 
No serious adverse event occurred during the study. 
Nine subjects on dronedarone, and four on placebo pre-
sented with treatment-emergent adverse events: one 
loose stool, two cases of fatigue, one injury, two cases of 
Table 1 
Placebo Dronedarone Geometric means (coefficient of 
Study variables Day-1 Day7 Day-1 Day 7 Pvalue 
C4 Sin (ml min-1) 106 (240/o) 107 (19%) 101 (36%) 98 (60%) NS 
C4 Cr (ml min-1) 142 (15%) 149 (120/o) 138 (340/o) 119 (59%) 0.04 
C4 PAH (ml min-1) 514 (24%) 513 (140/o) 515 (38%) 486 (66%) N.S. 
C4 NMN (ml min-1) 435 (250/o) 430 (20%) 448 (390/o) 368 (70%) 0.06 
C4 Cr : CLR Sin 1.34 (170/o) 1.39 (15%) 1.37 (19%) 1.21 (12%) 0.0001 
C4 NMN: CLR PAH 0.85 (25%) 0.84 (20%) 0.87 (20%) 0.76 (35%) 0.007 
CLR renal clearance; Sin, sinistrin; Cr, creatinine; PAH, para-amino-hippurate; NMN, 
N-methylnicotinamide; CLR Cr: CLR Sin, ratio of renal clearances of creatinine over 
sinistrin,- CLR NMN: CLR PAH, ratio of rena/ clearances of N-methylnicotinamide over 
para-amino-hippurate. NS: non significant 
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variation, %) of renal and systemic 
clearances according to treatment and 
study day 
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back pain, one musculoskeletal pain, one dizziness, five 
cases of headache, two cases of nasal congestion and 
one erythema after dronedarone treatment; one dyspep-
sia, one back pain, one myalgia and two cases of head-
ache after placebo treatment. No clinically relevant 
changes were observed in the laboratory tests. 
Discus;sion 
The results of this study indicate that dronedarone bas no 
influence on renal clearance of sinistrin, and therefore 
does not affect the glomerular filtration rate in the 
study subjects. By contrast, dronedarone significantly 
decreases renal creatinine clearance by about 18%. This 
observation is consistent with an inhibition of the cat-
ionic transport system by this antiarrhythmic drug, in a 
way similar to cimetidine. Interestingly, a similar effect 
bas been confirmed for amiodarone during long-term 
therapy [29]. 
A significant and similar decrease was observed in the 
renal clearance of another cation, NMN. Renal clearance 
of the anion PAH was not affected. This tends to confirm 
an inhibitory action of dronedarone specifically on the 
tubular cation transport system. The carriers involved in 
drug transportation being polyspecific, dronedarone 
could have a higher affinity than other drugs eliminated 
in this way, thus leading to their decreased clearance. 
The fact that PAH clearance remained stable indicates 
that renal plasma flow was not affected by dronedarone. 
NMN has also been proposed as an endogenous marker 
for the determination of renal blood flow [l, 26, 30]. 
This study indicates however, that it is less efficiently 
z 450 
I: 
z ... 350 
...J 
u I 250 
7 14 Day -1 7 14 
removed from renal blood than PAH, as its clearance is 
20% to 30% lower. Moreover, NMN may be affected by 
inhibitors of cationic transport, but similarly PAH is 
known to be influenced by anion transporter inhibitors 
[31-33]. Other variables ofrenal physiology like diure-
sis, renal filtration fraction, urinary sodium and potas-
sium excretion and osmolality, measured under strict 
standardization of food and fluid intake, remained unaf-
fected after 7 days of dronedarone treatment, which sug-
gests an absence of any other renal eff ects of this drug. 
Creatinine clearance impairment by dronedarone, 
though compatible with an inhibition of the OCT 
system, was lower than expected. Had tubular creatinine 
secretion been completely blocked by dronedarone, the 
ratio between renal creatinine and renal sinistrin clear-
ances would have reached 1.0, as observed with cimeti-
dine for example. In fact, the observed ratio decreased 
only to 1.2, while it remained at 1.4 on placebo, meaning 
a partial inhibition of the tubular creatinine secretion. 
This could be related either to an inhibition by drone-
darone of only certain subclasses of the OCT system, 
while creatinine may be secreted by other transporters, 
including OATs, or to incomplete inhibition of creatinine 
transport at the dose administered. Further studies are 
warranted to investigate the dose-dependency of this 
interference of dronedarone on the renal handling of 
creatinine. It would be of interest to determine whether 
the drug has any effect on creatinine clearance after full 
inhibition of tubular secretion by cimetidine, or whether 
it affects Cystatin C plasma concentrations. It would 
also be important to assess the effect of dronedarone on 
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other cationic drugs undergoing tubular secretion as a 
major route of elimination. Such a mechanism of drug 
interactions aff ecting cationic transport has been shown, 
for example, for amantadine (interaction with quinine 
and quinidine) [24, 34], metformin (interaction with 
cimetidine) [35] and procainamide (inhibited by trime-
thoprim) [36], and may induce adverse events. 
In conclusion, our results show that dronedarone 
reduces renal creatinine clearance by about 18% in 
healthy subjects, without affecting GFR, as confirmed 
by unchanged sinistrin clearance. This new antiarrhyth-
mic agent is thought to inhibit partially the renal cation 
transport system involved in creatinine and NMN secre-
tion, like cimetidine, trimethoprim or amiodarone, and 
does not seem to have other effects on renal physiology. 
This suggests a potential for drug interactions involving 
cationic drugs. Dronedarone may induce a limited 
increase in serum creatinine, which is not correlated to 
a decline in renal fonction. 
We would like to thank Monique Appenzelle1; Monique 
Salvi, Ali Maghraoui, Philippe Rousso and Yannick 
Perrin for their valuable contribution to this work. The 
sponsor of the study was Sanofi-Aventis. 
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